Suspicious Ultrasound Characteristics Predict BRAFV600E-Positive Papillary Thyroid Carcinoma

被引:52
|
作者
Kabaker, Adam S. [1 ]
Tublin, Mitchell E. [2 ]
Nikiforov, Yuri E. [3 ]
Armstrong, Michaele J. [1 ]
Hodak, Steven P. [4 ]
Stang, Michael T. [1 ]
McCoy, Kelly L. [1 ]
Carty, Sally E. [1 ]
Yip, Linwah [1 ]
机构
[1] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Dept Endocrinol, Pittsburgh, PA 15213 USA
关键词
PREOPERATIVE ULTRASONOGRAPHY; SURGICAL-MANAGEMENT; BRAF MUTATION; NODULES; CANCER; RISK; MALIGNANCY;
D O I
10.1089/thy.2011.0274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Current American Thyroid Association (ATA) guidelines recommend routine cervical ultrasound (US) in thyroid nodule evaluation. Specific US characteristics can help diagnose papillary thyroid carcinoma (PTC). The aim of this blinded cohort study was to determine whether these specific US characteristics can also reliably detect the more aggressive variants of PTC that are often associated with the BRAF(V600E) mutation. Methods: After Institutional Review Board approval, we identified a cohort of patients from January 2007 to December 2009 with histologic PTC 1 cm who had cervical US, initial thyroid surgery, and molecular testing for BRAF(V600E) on fine-needle aspiration biopsy or histology. Preoperative US images were evaluated by a single radiologist, who was blinded to BRAF status, for nodule size and the presence or absence of the following suspicious US features: taller-than-wide shape, ill-defined margins, hypoechogenicity, calcifications, noncystic composition, and absent halo. Results: BRAF-positivity was associated with most known suspicious US findings, including taller-than-wide shape (47% vs. 7%, p<0.001), ill-defined margins (42% vs. 9%, p<0.001), hypoechogenicity (83% vs. 36%, p<0.001), micro/macrocalcifications (87% vs. 24%, p<0.001), and absent halo (85% vs. 27%, p<0.001) but was not associated with noncystic composition. When 3 suspicious US features were present, BRAF-positivity was predicted with a positive predictive value of 82%. The absence of suspicious US features together with negative BRAF testing predicted PTC without extrathyroidal extension or lymph node metastasis (negative predictive value 88%). Conclusions: With routine preoperative cervical US and molecular testing, a trained radiologist or surgeon can improve the preoperative characterization of PTC, potentially impacting risk stratification and initial surgical management.
引用
收藏
页码:585 / 589
页数:5
相关论文
共 50 条
  • [1] Simultaneous Hodgkin lymphoma and BRAFV600E-positive papillary thyroid carcinoma A case report
    Liu, Shu
    Zhao, Yanru
    Li, Miaojing
    Xi, Jieying
    Shi, Bingyin
    Zhu, Huachao
    MEDICINE, 2019, 98 (03)
  • [2] Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer Response
    Brose, Marcia S.
    Singh, Nathan
    LANCET ONCOLOGY, 2016, 17 (11): : E469 - E469
  • [3] BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma
    Lim, Annette M.
    Taylor, Graham R.
    Fellowes, Andrew
    Cameron, Laird
    Lee, Belinda
    Hicks, Rodney J.
    McArthur, Grant A.
    Angel, Christopher
    Solomon, Benjamin
    Rischin, Danny
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (03): : 249 - 254
  • [4] Can Suspicious Ultrasound Features Predict BRAFV600E Status in Papillary Thyroid Cancer?
    Khadra, Helmi
    Deniwar, Ahmed
    Mohsin, Khuzema
    Monlezun, Dominique
    Kandil, Emad
    EUROPEAN THYROID JOURNAL, 2018, 7 (04) : 205 - 210
  • [5] Can Suspicious Surgeon's Performed Ultrasound Features Predict BRAFV600E Status in Papillary Thyroid Carcinoma?
    Deniwar, A.
    Bhatia, P.
    Al-Qurayshi, Z.
    Mohamed, H.
    Kandil, E.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S99 - S99
  • [6] Can Suspicious Surgeon-Performed Ultrasound Features Predict BRAFV600E Status in Papillary Thyroid Carcinoma?
    Khadra, H.
    Mohsin, K.
    Murad, F.
    Monlezun, D.
    Kandil, E.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S97 - S97
  • [7] The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAFV600E-Positive Papillary and Anaplastic Thyroid Carcinoma
    Vanden Borre, Pierre
    McFadden, David G.
    Gunda, Viswanath
    Sadow, Peter M.
    Varmeh, Shohreh
    Bernasconi, Maria
    Jacks, Tyler
    Parangi, Sareh
    THYROID, 2014, 24 (04) : 705 - 714
  • [8] BRAFV600E and Recurrence in Papillary Carcinoma Thyroid
    Kumari, N.
    George, N.
    Shukla, P.
    Vishwakarma, R.
    Agarwal, A.
    Krishnani, N.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 827 - 827
  • [9] Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV600E-Positive Papillary Thyroid Cancer
    da Silva, Sabrina Daniela
    Morand, Gregoire B.
    Diesel, Luciana
    de Lima, Jefferson Muniz
    Bijian, Krikor
    Kailasam, Senthilkumar
    Lefebvre, Francois
    Bourque, Guillaume
    Hier, Michael
    Alaoui-Jamali, Moulay A.
    CELLS, 2023, 12 (01)
  • [10] The Role of BRAFV600E Mutation and Ultrasonography for the Surgical Management of a Thyroid Nodule Suspicious for Papillary Thyroid Carcinoma on Cytology
    Moon, Hee Jung
    Kwak, Jin Young
    Kim, Eun-Kyung
    Choi, Jong Rak
    Hong, Soon Won
    Kim, Min Jung
    Son, Eun Ju
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (11) : 3125 - 3131